[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Grenier J, Delbaldo C, Zelek L, Piedbois P: [Phyllodes tumors and breast sarcomas: a review]. Bull Cancer; 2010 Oct;97(10):1197-207
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Phyllodes tumors and breast sarcomas: a review].
  • [Transliterated title] Tumeurs phyllodes et sarcomes du sein: mise au point.
  • Phyllodes tumors and sarcomas of the breast are non-epithelial tumors of the breast.
  • Phyllodes tumors are benign tumors, tumors of intermediate malignancy or malignant tumors.
  • The differential diagnosis with a very proliferant fibroadenoma may be difficult.
  • Histological sub-type, type of surgery (definitive or not) and stromal proliferation determine the prognosis.
  • Surgery (often radical) is the standard treatment.
  • Radiotherapy is recommended in case of high-grade tumor and after conservativetreatment.
  • Breast sarcomas are even rarer.
  • All histological types exist with a predominance of histiofibrocytome type tumors.
  • Grade, involved margins and sometimes tumor necrosis are major prognostics factors.
  • Among the various sub-types, angiosarcoma is characterized by a high risk of occurrence in irradiated fields and by a poor prognosis with a high risk of lung metastases.
  • The treatment is mostly based on mastectomy without lymph node dissection given the exceptional flooding axillary.
  • In some situations, a conservative treatment can be discussed, based on tumor size, grade and volume of the breast.
  • Systemic chemotherapy is not a standard but should be discussed in the forms at high risk of relapse (like angiosarcoma).
  • [MeSH-major] Breast Neoplasms / pathology. Phyllodes Tumor / pathology. Sarcoma / pathology
  • [MeSH-minor] Female. Hemangiosarcoma / pathology. Hemangiosarcoma / secondary. Hemangiosarcoma / therapy. Humans. Neoplasm Recurrence, Local. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20855241.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  •  go-up   go-down


2. Parker SJ, Harries SA: Phyllodes tumours. Postgrad Med J; 2001 Jul;77(909):428-35
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phyllodes tumours.
  • Phyllodes tumours are rare fibroepithelial lesions that account for less than 1% of all breast neoplasms.
  • With the non-operative management of fibroadenomas widely adopted, the importance of phyllodes tumours today lies in the need to differentiate them from other benign breast lesions.
  • All breast lumps should be triple assessed and the diagnosis of a phyllodes tumour considered in women, particularly over the age of 35 years, who present with a rapidly growing "benign" breast lump.
  • Treatment can be by either wide excision or mastectomy provided histologically clear specimen margins are ensured.
  • Approximately 20% of patients with malignant phyllodes tumours develop distant metastases.
  • The role of chemotherapy, radiotherapy, and hormonal manipulation in both the adjuvant and palliative settings remain to be defined.
  • [MeSH-major] Breast Neoplasms / diagnosis. Phyllodes Tumor / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aust N Z J Surg. 1988 Apr;58(4):301-5 [2855393.001]
  • [Cites] Cancer. 1989 Oct 1;64(7):1486-9 [2550124.001]
  • [Cites] Ann R Coll Surg Engl. 1989 Sep;71(5):285-8 [2552895.001]
  • [Cites] Surg Gynecol Obstet. 1990 Mar;170(3):193-6 [2154867.001]
  • [Cites] Br J Surg. 1966 May;53(5):450-5 [4378155.001]
  • [Cites] J Clin Invest. 1990 Apr;85(4):1320-3 [2156899.001]
  • [Cites] Am J Clin Pathol. 1990 Apr;93(4):480-5 [2157332.001]
  • [Cites] Eur J Surg Oncol. 1990 Jun;16(3):215-9 [2161352.001]
  • [Cites] Br J Clin Pract Suppl. 1989 Nov;68:147-9; discussion 157-8 [2562204.001]
  • [Cites] Zentralbl Chir. 1991;116(5):327-36 [1647600.001]
  • [Cites] Clin Radiol. 1991 Jul;44(1):8-12 [1651822.001]
  • [Cites] AJR Am J Roentgenol. 1991 Oct;157(4):715-9 [1654022.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):2017-22 [1655234.001]
  • [Cites] Cancer. 1992 Jan 1;69(1):141-7 [1309302.001]
  • [Cites] Am Surg. 1994 Aug;60(8):583-5 [8030812.001]
  • [Cites] Pathol Res Pract. 1994 May;190(5):474-81 [7991467.001]
  • [Cites] Acta Cytol. 1994 Nov-Dec;38(6):891-7 [7992575.001]
  • [Cites] Am Surg. 1995 Apr;61(4):350-5 [7893104.001]
  • [Cites] Ann R Coll Surg Engl. 1995 May;77(3):181-4 [7598414.001]
  • [Cites] Breast Cancer Res Treat. 1998 Apr;48(3):205-10 [9598867.001]
  • [Cites] Ann Acad Med Singapore. 1998 Mar;27(2):200-3 [9663310.001]
  • [Cites] Diagn Cytopathol. 1999 Feb;20(2):53-6 [9951596.001]
  • [Cites] Eur Radiol. 1999;9(2):356-60 [10101663.001]
  • [Cites] Br J Surg. 1999 Mar;86(3):396-9 [10201787.001]
  • [Cites] Arch Surg. 1999 May;134(5):487-92; discussion 492-3 [10323420.001]
  • [Cites] Histopathology. 1999 Jun;34(6):491-6 [10383692.001]
  • [Cites] Eur J Surg Oncol. 1999 Aug;25(4):352-5 [10419703.001]
  • [Cites] Histopathology. 1999 Aug;35(2):162-9 [10460662.001]
  • [Cites] Aust N Z J Surg. 1999 Sep;69(9):635-8 [10515335.001]
  • [Cites] Cancer. 1951 Nov;4(6):1286-1332 [14886887.001]
  • [Cites] Cancer. 1954 Mar;7(2):335-53 [13141227.001]
  • [Cites] Br J Surg. 1961 Mar;48:519-21 [13685750.001]
  • [Cites] Ann Surg. 1950 Feb;131(2):243-51, illust [15402797.001]
  • [Cites] Cancer. 1965 Jun;18:697-710 [14297466.001]
  • [Cites] Cancer Res. 1992 Jul 15;52(14):4046-9 [1319837.001]
  • [Cites] Acta Cytol. 1992 Mar-Apr;36(2):203-7 [1311887.001]
  • [Cites] Acta Cytol. 1992 Mar-Apr;36(2):215-21 [1311889.001]
  • [Cites] Cancer. 1992 May 1;69(9):2271-5 [1314127.001]
  • [Cites] Eur J Cancer. 1992;28(2-3):654-7 [1317204.001]
  • [Cites] Aust N Z J Surg. 1992 Aug;62(8):628-33 [1322660.001]
  • [Cites] Mod Pathol. 1992 May;5(3):232-9 [1323101.001]
  • [Cites] Cancer. 1992 Oct 15;70(8):2115-20 [1327488.001]
  • [Cites] Eur J Radiol. 1992 Jul-Aug;15(1):11-4 [1327792.001]
  • [Cites] Eur J Surg Oncol. 1992 Dec;18(6):545-9 [1335886.001]
  • [Cites] Eur J Surg Oncol. 1993 Feb;19(1):70-3 [8382173.001]
  • [Cites] Am J Surg. 1993 Mar;165(3):376-9 [8383473.001]
  • [Cites] Cancer. 1993 May 15;71(10):3020-4 [8387873.001]
  • [Cites] Eur J Cancer. 1993;29A(9):1252-6 [8393684.001]
  • [Cites] Cancer Res. 1993 Sep 1;53(17):4071-4 [8395336.001]
  • [Cites] Am J Surg. 1994 May;167(5):477-80 [8185030.001]
  • [Cites] J Surg Oncol. 1994 Jun;56(2):108-12 [8007675.001]
  • [Cites] Histopathology. 1995 Sep;27(3):205-18 [8522284.001]
  • [Cites] Radiology. 1996 Jan;198(1):121-4 [8539362.001]
  • [Cites] J Natl Cancer Inst. 1996 Jan 17;88(2):116-22 [8537972.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):910-6 [8608483.001]
  • [Cites] Surg Clin North Am. 1996 Apr;76(2):383-92 [8610270.001]
  • [Cites] Cancer. 1995 Nov 15;76(10):1779-85 [8625047.001]
  • [Cites] AJR Am J Roentgenol. 1996 Jul;167(1):187-9 [8659370.001]
  • [Cites] J R Coll Surg Edinb. 1996 Aug;41(4):244-5 [8772074.001]
  • [Cites] Acta Cytol. 1997 Mar-Apr;41(2):321-6 [9100761.001]
  • [Cites] Cytopathology. 1997 Jun;8(3):177-87 [9202893.001]
  • [Cites] Am J Surg Pathol. 1998 Jan;22(1):64-9 [9422317.001]
  • [Cites] Johns Hopkins Med J. 1967 Jan;120(1):33-45 [4289572.001]
  • [Cites] Cancer. 1967 Dec;20(12):2090-9 [4294565.001]
  • [Cites] Oncology. 1968;22(2):145-58 [4301320.001]
  • [Cites] Ann Surg. 1970 Jun;171(6):849-56 [4316088.001]
  • [Cites] Can J Surg. 1971 Jan;14(1):31-7 [4322170.001]
  • [Cites] Ann Surg. 1971 Apr;173(4):520-8 [4324792.001]
  • [Cites] J Surg Oncol. 1972;4(2):131-47 [4338176.001]
  • [Cites] Br J Surg. 1974 Feb;61(2):113-7 [4361232.001]
  • [Cites] Am Surg. 1974 May;40(5):295-301 [4362487.001]
  • [Cites] Ann Surg. 1974 Nov;180(5):796-8 [4370747.001]
  • [Cites] Surg Gynecol Obstet. 1975 Jun;140(6):929-32 [165582.001]
  • [Cites] Cancer. 1976 Apr;37(4):1737-46 [177175.001]
  • [Cites] Arch Surg. 1976 May;111(5):611 [178291.001]
  • [Cites] Cancer. 1976 Sep;38(3):1402-6 [182356.001]
  • [Cites] Surg Gynecol Obstet. 1978 Mar;146(3):358-64 [204070.001]
  • [Cites] Cancer. 1978 May;41(5):1974-83 [206344.001]
  • [Cites] Am J Clin Pathol. 1978 Aug;70(2):211-6 [211844.001]
  • [Cites] Cancer. 1981 Apr 15;47(8):2016-21 [6261932.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1981;392(1):1-6 [6269275.001]
  • [Cites] Am Surg. 1982 Apr;48(4):157-66 [6282155.001]
  • [Cites] Am J Surg. 1982 Sep;144(3):341-3 [6287874.001]
  • [Cites] Cancer Detect Prev. 1982;5(2):211-9 [6290062.001]
  • [Cites] Radiol Clin North Am. 1983 Mar;21(1):27-50 [6300955.001]
  • [Cites] Am J Surg. 1983 Dec;146(6):712-4 [6316797.001]
  • [Cites] Arch Intern Med. 1985 Jun;145(6):1127-8 [2988474.001]
  • [Cites] Arch Gynecol. 1985;236(3):173-81 [2990358.001]
  • [Cites] Cancer. 1986 Nov 15;58(10):2282-9 [3019505.001]
  • [Cites] Am J Surg. 1987 Mar;153(3):276-80 [3030151.001]
  • [Cites] Clin Radiol. 1987 May;38(3):287 [3034476.001]
  • [Cites] Br J Surg. 1987 Sep;74(9):857-9 [3664257.001]
  • [Cites] Acta Cytol. 1988 Jan-Feb;32(1):63-6 [3336956.001]
  • [Cites] Acta Pathol Jpn. 1988 Jan;38(1):21-33 [2834912.001]
  • [Cites] Arch Pathol Lab Med. 1988 Jul;112(7):752-6 [2838007.001]
  • [Cites] Arch Surg. 1988 Sep;123(9):1079-83 [2843145.001]
  • [Cites] Surgery. 1989 Feb;105(2 Pt 1):141-7 [2536964.001]
  • [Cites] Cancer. 1989 Jun 1;63(11):2088-92 [2541882.001]
  • [Cites] Cancer. 1989 Jun 15;63(12):2532-6 [2541890.001]
  • (PMID = 11423590.001).
  • [ISSN] 0032-5473
  • [Journal-full-title] Postgraduate medical journal
  • [ISO-abbreviation] Postgrad Med J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 111
  • [Other-IDs] NLM/ PMC1760996
  •  go-up   go-down


3. Sugie T, Takeuchi E, Kunishima F, Yotsumoto F, Kono Y: A case of ductal carcinoma with squamous differentiation in malignant phyllodes tumor. Breast Cancer; 2007;14(3):327-32
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of ductal carcinoma with squamous differentiation in malignant phyllodes tumor.
  • Carcinoma derived from the lining epithelial cells in malignant phyllodes tumor is a rare neoplasm of the breast and belongs to the category of carcinosarcoma.
  • We report a case of ductal carcinoma with squamous differentiation arising in malignant phyllodes tumor.
  • A 54-year-old woman was admitted with a rapidly enlarging left breast mass.
  • A breast tumor with a diameter of 6 cm was located mainly in the left outer area of the breast.
  • Mammography revealed a high-density mass with an irregular margin and ultrasound showed a cystic tumor.
  • A pathological diagnosis of ductal carcinoma with squamous differentiation was made by fine needle aspiration and a core needle biopsy.
  • She underwent neoadjuvant chemotherapy followed by a modified radical mastectomy with a skin flap.
  • Histopathological examination revealed that the invasive ductal carcinoma with squamous differentiation originated from the lining epithelial cells in malignant phyllodes tumor and that there was no transition area between the carcinomatous and the sarcomatous component.
  • She experienced lung and facial bone metastases, microscopic features of which were consistent with the sarcomatous component of the original breast carcinosarcoma.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Neoplasms, Multiple Primary / diagnosis. Phyllodes Tumor / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Middle Aged

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690514.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Korula A, Varghese J, Thomas M, Vyas F, Korula A: Malignant phyllodes tumour with intraductal and invasive carcinoma and lymph node metastasis. Singapore Med J; 2008 Nov;49(11):e318-21
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant phyllodes tumour with intraductal and invasive carcinoma and lymph node metastasis.
  • Phyllodes tumours constitute 2-3 percent of fibroepithelial breast tumours, with a 1-2 percent rate of malignancy.
  • Carcinoma in a phyllodes tumour is distinctly uncommon, but has been known to occur in benign phyllodes tumours.
  • We describe a 51-year-old woman with a malignant phyllodes tumour with foci of intraductal carcinoma within the tumour and adjacent breast tissue.
  • Though the carcinoma was found to be invasive based on the presence of carcinomatous lymph node metastasis, extensive sampling did not yield an invasive component within the breast, probably because of the marked stromal overgrowth of the phyllodes.
  • A malignant phyllodes tumour with foci of intraductal carcinoma and axillary lymph node metastases was diagnosed rather than carcinosarcoma.
  • Chemotherapy and irradiation were included in the postoperative management.
  • Coexistence of phyllodes tumour and carcinoma is rare, and extensive sampling may be necessary to find the foci of carcinoma within an extensive and obviously malignant stromal overgrowth.
  • There is little consensus on the treatment and prognosis in these cases, and it is recommended that treatment be tailored to individual patients, based on the presence of invasion, lymph node metastasis and/or distant metastasis.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Carcinoma / diagnosis. Carcinoma / pathology. Phyllodes Tumor / diagnosis. Phyllodes Tumor / pathology
  • [MeSH-minor] Breast / pathology. Breast / surgery. Female. Humans. Immunohistochemistry. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19037540.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


5. Malard Y, De Lara CT, MacGrogan G, Bussières E, Avril A, Picot V, Bui B, Coindre JM: [Primary breast sarcoma. A retrospective study of 42 patients treated at the Bergonié Institute during a 32-year period]. J Gynecol Obstet Biol Reprod (Paris); 2004 Nov;33(7):589-99
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary breast sarcoma. A retrospective study of 42 patients treated at the Bergonié Institute during a 32-year period].
  • [Transliterated title] Sarcomes primitifs du sein: à propos d'une série rétrospective de 42 cas traités à l'Institut Bergonié sur une période de 32 ans.
  • To analyze Primary breast sarcomas (PBS).
  • To investigate treatment and prognostic factors influencing overall survival (OS) and disease-free survival (DFS).
  • RESULTS: The median age at diagnosis was 56.9 years (24-81 years).
  • Surgery was part of the therapeutic strategy in all the patients.
  • Patients with angiosarcoma and those with malignant cystosarcoma constituted distinct populations.
  • The 10-year OS and DFS rates were 53% and 55% for angiosarcoma patients and 89% and 100% for cystosarcoma patients (p=0.009 and 0.01 respectively).
  • CONCLUSION: Careful preoperative multidisciplinary assessment is required before making the decision to treat.
  • [MeSH-major] Breast Neoplasms / surgery. Sarcoma / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Hemangiosarcoma / drug therapy. Hemangiosarcoma / mortality. Hemangiosarcoma / radiotherapy. Hemangiosarcoma / surgery. Humans. Mastectomy. Middle Aged. Phyllodes Tumor / drug therapy. Phyllodes Tumor / mortality. Phyllodes Tumor / radiotherapy. Phyllodes Tumor / surgery. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15550877.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


6. Guerrero MA, Ballard BR, Grau AM: Malignant phyllodes tumor of the breast: review of the literature and case report of stromal overgrowth. Surg Oncol; 2003 Jul;12(1):27-37
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant phyllodes tumor of the breast: review of the literature and case report of stromal overgrowth.
  • Cystosarcoma phyllodes constitutes only 0.3-0.9% of all breast tumors.
  • The term "sarcoma" was initially used because of its fleshy appearance, a more modern term is Phyllodes tumor (PT).
  • The behavior of PT constitutes a spectrum from benign and locally recurrent to malignant and metastatic.
  • In a general surgical series, 6.2% of the tumors were malignant.
  • The microscopic appearance of PT is that of epithelial elements and connective tissue stroma.
  • The metastatic spread of malignant PT is mainly hematogenous to lung, with infrequent lymphatic involvement.
  • Wide local excision with 2 cm margins is the treatment of choice.
  • In 20% of both benign and malignant cases, PT will locally recur.
  • There is no proven benefit of radiation or chemotherapy, although radiotherapy may be useful in selected cases.
  • We present a case of a sarcomatous overgrowth in a malignant phyllodes tumor involving multiple histologic types.
  • [MeSH-major] Breast Neoplasms / surgery. Phyllodes Tumor / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12689668.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 56
  •  go-up   go-down


7. Morales-Vásquez F, Gonzalez-Angulo AM, Broglio K, Lopez-Basave HN, Gallardo D, Hortobagyi GN, De La Garza JG: Adjuvant chemotherapy with doxorubicin and dacarbazine has no effect in recurrence-free survival of malignant phyllodes tumors of the breast. Breast J; 2007 Nov-Dec;13(6):551-6
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy with doxorubicin and dacarbazine has no effect in recurrence-free survival of malignant phyllodes tumors of the breast.
  • The purpose of this study was to evaluate the role of adjuvant chemotherapy in malignant phyllodes tumors of the breast treated at the Instituto Nacional de Cancerología of Mexico.
  • Twenty-eight patients with malignant phyllodes tumors of the breast enrolled in a observational study from January 1993 to December 2003 to receive four cycles of adjuvant chemotherapy with doxorubicin 65 mg/m(2) over 48 hours intravenous infusion and dacarbazine 960 mg/m(2) over 48 hours intravenous infusion (n = 17) versus observation (n = 11).
  • The median tumor size was 13 cm (range, 3-30 cm), and 46% of the tumors were in the left breast.
  • The 5 year RFS rate was 58% (95% CI = 36% and 92%) for the patients who received adjuvant therapy and 86% (95% CI = 63% and 100%) for the patients who did not (p = 0.17).
  • Adjuvant chemotherapy with doxorubicin and dacarbazine did not affect patient survival.
  • Future studies to identify relevant molecular targets should be implemented in order to define effective therapies for phyllodes tumors of the breast.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Breast Neoplasms / drug therapy. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Phyllodes Tumor / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / administration & dosage. Chemotherapy, Adjuvant. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17983394.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin
  •  go-up   go-down


8. Büchler T, Vorzilková E, Koukolík F, Melínova H, Abrahámová J: [Malignant subtype of cystosarcoma phyllodes with brain metastases]. Klin Onkol; 2010;23(6):446-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant subtype of cystosarcoma phyllodes with brain metastases].
  • [Transliterated title] Maligní forma cystosarcoma phyllodes s metastázami do mozku.
  • Cystosarcoma phyllodes is an uncommon type of breast tumour.
  • Benign, borderline, and malignant subtypes have been described.
  • Central nervous system metastases of the malignant subtype of cystosarcoma phyllodes are rare and associated with poor prognosis.
  • We report on a patient with malignant cystosarcoma phyllodes who developed metastatic disease six years after resection of the primary breast tumour.
  • Partial regression of a brain metastasis was achieved using radiotherapy but the patient later died due to widespread metastatic disease which was uncontrollable by systemic chemotherapy.
  • Because metastatic malignant cystosarcoma phyllodes are largely resistant to treatment, the most important objective is to provide optimal management of the primary tumour before dissemination occurs.
  • [MeSH-major] Brain Neoplasms / secondary. Breast Neoplasms / pathology. Phyllodes Tumor / secondary

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21351423.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


9. Haberer S, Laé M, Seegers V, Pierga JY, Salmon R, Kirova YM, Dendale R, Campana F, Reyal F, Miranda O, Fourquet A, Bollet MA: [Management of malignant phyllodes tumors of the breast: the experience of the Institut Curie]. Cancer Radiother; 2009 Jul;13(4):305-12
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of malignant phyllodes tumors of the breast: the experience of the Institut Curie].
  • [Transliterated title] Prise en charge des tumeurs phyllodes malignes du sein: l'expérience de l'institut Curie.
  • PURPOSE: Given the scarcity of malignant phyllode tumours of the breast and the absence of consensus regarding their management justify the need for institutional retrospective evaluations of clinical practices.
  • PATIENTS AND METHODS: Retrospective study with central pathology review of the 25 consecutive patients treated at the Institut Curie (Paris, France) between 1969 and 2006 for non metastatic malignant phyllodes tumors of the breast.
  • RESULTS: Median age at diagnosis was 52 years (20-64 years).
  • Breast surgery was conservative in five patients (20%).
  • Median tumour size was 65 mm (12-250 mm).
  • Adjuvant radiotherapy was delivered in seven (28%) patients (two patients, post-tumorectomy; five patients, post-mastectomy) and 13 patients (52%) received anthracycline-based adjuvant chemotherapy.
  • Five patients (20%) developed distant metastases (one after chemotherapy) and three (12%) locoregional relapse (one after tumorectomy and unknown margin without radiotherapy, two after mastectomy and involved margins with radiotherapy).
  • CONCLUSION: Wide breast surgery (that can be conservative in selected patients) is the mainstay of the treatment of non metastatic malignant phyllodes tumors of the breast.
  • To better determine the respective roles of adjuvant systemic treatment and radiotherapy, further clinical studies and the search for new prognostic and predictive factors remain necessary.
  • [MeSH-major] Breast Neoplasms. Phyllodes Tumor
  • [MeSH-minor] Adult. Cancer Care Facilities. Chemotherapy, Adjuvant. Female. France. Humans. Mastectomy / methods. Middle Aged. Retrospective Studies. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19524472.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


10. Khan SA, Badve S: Phyllodes tumors of the breast. Curr Treat Options Oncol; 2001 Apr;2(2):139-47
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phyllodes tumors of the breast.
  • Phyllodes tumor is a rare fibroepithelial neoplasm of the breast with a very variable, but usually benign, course.
  • Formerly known as cystosarcoma phyllodes, the designation "phyllodes tumor" with appropriate qualification regarding malignant potential based on pathologic features is now the agreed-upon term.
  • The most important diagnostic distinction is from fibroadenoma--phyllodes tumors require complete excision with free margins even when pathologic features suggest benignity because of a proclivity to local recurrence.
  • The most important component of therapy is wide surgical excision, and mastectomy is necessary only when free margins cannot be achieved without it.
  • The role of radiation therapy and chemotherapy is not established and has not been studied in randomized trials due to the rarity of the tumor.
  • At present, there is no consensus that patients with high-grade phyllodes tumors of the breast will benefit from either of these modalities.
  • [MeSH-major] Breast Neoplasms / surgery. Phyllodes Tumor / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cisplatin / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Mastectomy. Mastectomy, Segmental. Practice Guidelines as Topic. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res Treat. 1999 Oct;57(3):291-5 [10617306.001]
  • [Cites] Am J Surg Pathol. 1998 Jan;22(1):64-9 [9422317.001]
  • [Cites] Radiat Oncol Investig. 1998;6(6):264-7 [9885942.001]
  • [Cites] Eur Radiol. 1999;9(2):356-60 [10101663.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Nov;20(3):275-81 [9365835.001]
  • [Cites] Cancer. 1989 Jun 1;63(11):2088-92 [2541882.001]
  • [Cites] Am J Surg Pathol. 1994 Jul;18(7):720-7 [8017566.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1994 May 18;54(3):197-203 [7926234.001]
  • [Cites] Arch Surg. 1999 May;134(5):487-92; discussion 492-3 [10323420.001]
  • [Cites] Am J Surg. 1994 May;167(5):477-80 [8185030.001]
  • [Cites] Histopathology. 1999 Jun;34(6):491-6 [10383692.001]
  • [Cites] Ann R Coll Surg Engl. 1995 May;77(3):181-4 [7598414.001]
  • [Cites] Cancer. 2000 Oct 1;89(7):1502-11 [11013364.001]
  • [Cites] Br J Surg. 1999 Mar;86(3):396-9 [10201787.001]
  • [Cites] Am Surg. 2000 Apr;66(4):360-6 [10776873.001]
  • [Cites] Ann Nucl Med. 1997 Feb;11(1):37-9 [9095321.001]
  • [Cites] J Pediatr Surg. 1995 Feb;30(2):322-4 [7738758.001]
  • [Cites] Breast Cancer Res Treat. 1998 Apr;48(3):205-10 [9598867.001]
  • [Cites] Am Surg. 1994 Aug;60(8):583-5 [8030812.001]
  • [Cites] Aust N Z J Surg. 1988 Apr;58(4):301-5 [2855393.001]
  • [Cites] Eur J Cancer. 1993;29A(9):1252-6 [8393684.001]
  • [Cites] Am J Surg Pathol. 1999 Jul;23(7):815-21 [10403305.001]
  • [Cites] Pathol Int. 1999 Sep;49(9):807-10 [10504552.001]
  • [Cites] Histopathology. 1995 Sep;27(3):205-18 [8522284.001]
  • [Cites] Cancer. 1995 Nov 15;76(10):1779-85 [8625047.001]
  • [Cites] Pathol Res Pract. 1994 May;190(5):474-81 [7991467.001]
  • [Cites] Histopathology. 1996 Nov;29(5):411-9 [8951485.001]
  • [Cites] Cancer. 1993 May 15;71(10):3020-4 [8387873.001]
  • [Cites] Cancer. 1992 May 1;69(9):2271-5 [1314127.001]
  • [Cites] Cancer Lett. 1995 Mar 23;90(1):57-63 [7720044.001]
  • [Cites] Arch Intern Med. 1985 Jun;145(6):1127-8 [2988474.001]
  • (PMID = 12057132.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 32
  •  go-up   go-down


11. Shabbir J, O'Sullivan JB, Mahmood S, Byrnes G: Phyllodes tumor of breast. J Coll Physicians Surg Pak; 2003 Mar;13(3):170-1
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phyllodes tumor of breast.
  • Phyllodes tumors account for 0.3%-0.5% of all the breast tumors.
  • They are usually benign but malignant variants exist and have the potential to metastasize.
  • Surgery is the mainstay of treatment as there is no proven benefit of adjuvant chemotherapy or radiotherapy.
  • We are presenting a case of 42 years old female with benign phyllodes tumor and a brief review of literature on the subject.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / surgery. Phyllodes Tumor / pathology. Phyllodes Tumor / surgery
  • [MeSH-minor] Adult. Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Mastectomy, Segmental / methods. Rare Diseases. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12689541.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


12. Pandey M, Mathew A, Kattoor J, Abraham EK, Mathew BS, Rajan B, Nair KM: Malignant phyllodes tumor. Breast J; 2001 Nov-Dec;7(6):411-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant phyllodes tumor.
  • The study aims to evaluate the survival and prognosis of patients with malignant phyllodes tumor.
  • Between 1982 and 1998, 37 women with malignant phyllodes tumor were treated at the Regional Cancer Center, Trivandrum.
  • Patient, disease, and treatment factors were compared using log-rank test.
  • Twenty-five patients received postoperative radiotherapy, and 2 received chemotherapy in addition.
  • However, patients with tumor size more than 5 cm (hazard ratio 2.9) were found to have increased hazard, whereas those receiving adjuvant radiotherapy (hazard ratio 0.6), married women (hazard ratio 0.4), and those women over the age of 35 years (hazard ratio 0.7) showed a decreased hazards.
  • Cystosarcoma phyllodes is a rare malignancy of the female breast.
  • Surgery with adequate margins is the primary treatment.
  • [MeSH-major] Breast Neoplasms / mortality. Phyllodes Tumor / mortality

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11843853.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Erhan Y, Zekioglu O, Ersoy O, Tugan D, Aydede H, Sakarya A, Kapkaç M, Ozdemir N, Ozbal O, Erhan Y: p53 and Ki-67 expression as prognostic factors in cystosarcoma phyllodes. Breast J; 2002 Jan-Feb;8(1):38-44
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 and Ki-67 expression as prognostic factors in cystosarcoma phyllodes.
  • We have reviewed the histopathological, clinical outcome and immunohistochemical status in 21 women with cystosarcoma phyllodes (CSP) tumors of the breast.
  • We assessed 12 tumors as histopathologically benign and 9 tumors as malignant.
  • The median patient ages in benign and malignant CSP tumors were 39.6 and 45.4 years of age, respectively.
  • The stromal cellularity, stromal cellular atypism, high mitotic activity, atypic mitoses, stromal overgrowth, infiltrative tumor contour, and heterologous stromal elements were significant features of the malignant CSP tumors.
  • Five malignant CSP tumors were stained positively with p53, and 6 malignant CSP tumors were stained immunohistochemically with Ki-67.
  • Malignant CSP tumors were treated with wide local excision ( n=1), partial mastectomy ( n=1), simple mastectomy ( n=2), and modified radical mastectomy ( n=5).
  • Two patients with a high mitotic rate and high values of p53 and Ki-67 received additional radiotherapy and chemotherapy.
  • This tumor had high mitotic figures, stromal overgrowth, severe stromal cellularity, and 20% Ki-67 and mild p53 positivity.
  • We suggest that p53 and Ki-67 can play an important role in predicting prognosis and yielding additional therapy besides conventional prognostic factors in the treatment of the CSP patients.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Ki-67 Antigen / metabolism. Phyllodes Tumor / metabolism. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11856160.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


14. Ramon Y Cajal T, Mazarico J, Lopez Pousa A, Quintana M, Sala N, Altabas M, Sebio A, Robert L, Alonso C, Barnadas A: Clinical features and outcome in primary breast sarcomas (BS): Analysis of a single-institution experience. J Clin Oncol; 2009 May 20;27(15_suppl):e21520

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and outcome in primary breast sarcomas (BS): Analysis of a single-institution experience.
  • Controversy remains about local and adjuvant treatment.
  • METHODS: We analyzed clinicopathological variables, treatment and outcome of 33 BS patients treated at our institution from 1966 to 2007.
  • Tumor size 57 (0-230) mm.
  • Pathology: 17 cistosarcoma phylodes (CPh), 9 angiosarcoma, 2 extraesqueletical osteosarcoma, 2 fibrosarcomas, 1 liposarcoma, 1 leiomiosarcoma, 1 malignant fibrous histiocitoma (2.9%).
  • Adjuvant chemotherapy and radiotherapy in 9 and 7 patients.
  • 7 pts death only 1 phyllodes.
  • Radical surgery in BS should be always considered as first treatment option.
  • High-grade non-phylodes BS types may be considered for adjuvant chemotherapy although there were non-statistical differences in OS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963450.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Confavreux C, Lurkin A, Mitton N, Blondet R, Saba C, Ranchère D, Sunyach MP, Thiesse P, Biron P, Blay JY, Ray-Coquard I: Sarcomas and malignant phyllodes tumours of the breast--a retrospective study. Eur J Cancer; 2006 Nov;42(16):2715-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomas and malignant phyllodes tumours of the breast--a retrospective study.
  • BACKGROUND: Although most breast cancers are adenocarcinomas of the mammary gland, primary breast sarcomas may also arise from mammary gland mesenchymal tissue.
  • The annual incidence of primary breast sarcoma is low and has been estimated at 45 new cases per 10 million women.
  • Phyllodes tumours represent a specific subset of these breast soft tissue tumours.
  • They are composed of a connective tissue stroma and epithelial elements.
  • Pathological presentation ranges from grade I to malignant phyllodes tumours (grade III) where the stromal component clearly exhibits a sarcoma pattern.
  • SAPHYR aims to describe the characteristics of primary breast sarcomas and to define potential survival factors to be evaluated in future prospective studies.
  • No survival difference was found between malignant phyllodes (grade III) and other primary breast sarcomas (angiosarcomas excluded).
  • Histology revealed three significantly (p=0.0003) different prognostic groups: phyllodes grade I and II (DFS=57%), angiosarcomas (DFS=7%) and phyllodes grade III and other primary breast sarcomas (DFS=45%).
  • DISCUSSION: Phyllodes tumours and primary breast sarcomas are totally different from epithelial breast cancers and should be considered as a distinct group of rare tumours.
  • The first goal of treatment is to achieve negative margins (R0).
  • We propose to treat the patients according to the clinical practice guidelines in use for soft tissue sarcomas and address them to a reference centre for sarcoma.
  • Treating rare tumours in the same place should permit us to standardise pathological data and to include patients into multicentric radiotherapy or chemotherapy protocols to improve overall survival.
  • [MeSH-major] Breast Neoplasms. Phyllodes Tumor. Sarcoma
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17023158.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Soumarová R, Seneklová Z, Horová H, Vojkovská H, Horová I, Budíková M, Růzicková J, Jezková B: Retrospective analysis of 25 women with malignant cystosarcoma phyllodes--treatment results. Arch Gynecol Obstet; 2004 May;269(4):278-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of 25 women with malignant cystosarcoma phyllodes--treatment results.
  • PURPOSE: Mastectomy without axillary dissection should be the standard treatment in patients with malignant form of cystosarcoma phyllodes.
  • The role of postoperative radiotherapy and chemotherapy remains to be fully established.
  • We evaluate treatment results in a group of patients with cystosarcoma phyllodes (CP) treated at our Institute.
  • PATIENTS AND METHODS: In this report we analyze treatment outcome in 25 patients with malignant cystosarcoma phyllodes treated at Masaryk Memorial Cancer Institute between 1970 and 1995.
  • Mean tumor size was 10 cm in diameter.
  • Subsequently, 17 patients (68%) received radiotherapy on the breast or chest wall.
  • Time to local relapse after surgery was 4-11 months.
  • CONCLUSION: A specific protocol for the treatment of cystosarcoma phyllodes is missing, probably due to rarity of the disease.
  • The treatment of local recurrent disease remains unsuccessful in most CP patients.
  • We recommend postoperative irradiation on the chest wall in patients with malignant form of CP, because adjuvant radiotherapy decreased the incidence of local relapse in our group of patients.
  • [MeSH-major] Breast Neoplasms / epidemiology. Neoplasm Recurrence, Local / epidemiology. Phyllodes Tumor / epidemiology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Czech Republic / epidemiology. Disease-Free Survival. Female. Humans. Medical Records. Middle Aged. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15205980.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Udelnow A, Leinung S, Dannenberg C, Trantakis Ch, Schober R, Schönfelder M, Würl P: [A giant malignant tumour of the skull-Case report and differential diagnosis]. Zentralbl Chir; 2002 Mar;127(3):243-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A giant malignant tumour of the skull-Case report and differential diagnosis].
  • [Transliterated title] Ein gigantischer maligner Tumor der Kalotte - Fallbericht und Differentialdiagnose.
  • The case of a 72-year-old woman with a high-partially located tumor grown within a half year to a magnitude of 8.5 x 11 x 11 cm is reported.
  • The patient remembered a mastectomy and axillary lymphadenectomy followed by chemotherapy and radiation 8 years ago.
  • Therefore we assumed a skeletal metastasis of a breast cancer.
  • Searching for the pathohistological evaluation of the former breast tumor, a cystosarcoma phylloides malignum could be found out.
  • The tumor described here can be identified as a metastasis of this rare neoplasm.
  • [MeSH-major] Breast Neoplasms / diagnosis. Phyllodes Tumor / secondary. Skull Neoplasms / secondary
  • [MeSH-minor] Aged. Craniotomy. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Parietal Lobe / pathology. Parietal Lobe / surgery. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11935491.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Fajdić J, Gotovac N, Hrgović Z, Kristek J, Horvat V, Kaufmann M: Phyllodes tumors of the breast diagnostic and therapeutic dilemmas. Onkologie; 2007 Mar;30(3):113-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phyllodes tumors of the breast diagnostic and therapeutic dilemmas.
  • BACKGROUND: This article compares experiences in the diagnosis and treatment of phyllodes tumors from 2 regional institutions with the relevant literature.
  • PATIENTS AND METHODS: From 1991 to 2005, 2,848 breast cancer patients were treated in our institutions, 36 (1.44%) for phyllodes tumors.
  • The average tumor size was 5.1 cm (range 1.4-19.6).
  • Wide excision with tumor-free margins was carried out in 29 (80.5%) cases and mastectomy in 7 (19.4%) cases.
  • RESULTS: Histology showed the phyllodes tumors to be benign in 27 (75.0%), malignant in 6 (16.6%), and borderline in 3 (8.3%) cases.
  • In this period, recurrences of 3 (8.3%) malignant and 2 (5.6%) benign phyllodes tumors were diagnosed and treated.
  • The steroid receptor status was of no prognostic value in our patients, and chemotherapy was used in only 1 (2.7%) patient.
  • CONCLUSION: Our study shows that tumor size, margin infiltration, mitotic activity and degree of cellular atypia are important prognostic factors.
  • Although wide local excision is usually the treatment of choice, tumor recurrence is common.
  • Axillary lymphadenectomy in malignant phyllodes tumors is, in our opinion, still controversial.
  • [MeSH-major] Breast Neoplasms / diagnosis. Phyllodes Tumor / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast / pathology. Diagnosis, Differential. Female. Humans. Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Mammography. Mastectomy. Mastectomy, Segmental. Middle Aged. Mitotic Index. Necrosis. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Prognosis. Reoperation. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17341897.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


19. Ueyama Y, Abe Y, Ohnishi Y, Sawa N, Hatanaka H, Handa A, Tokuda Y, Yamazaki H, Kijima H, Tamaoki N, Nakamura M: In vivo chemosensitivity of human malignant cystosarcoma phyllodes xenografts. Oncol Rep; 2000 Mar-Apr;7(2):257-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo chemosensitivity of human malignant cystosarcoma phyllodes xenografts.
  • Malignant cystosarcoma phyllodes (MCSP) is a rare breast tumor.
  • Chemotherapeutic regimens for treatment of MCSP have not been established.
  • We studied the chemosensitivity of these two MCSP tumor xenografts to anticancer drugs in vivo.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Breast Neoplasms / drug therapy. Cyclophosphamide / pharmacology. Doxorubicin / pharmacology. Drug Screening Assays, Antitumor. Phyllodes Tumor / drug therapy. Vincristine / pharmacology
  • [MeSH-minor] Animals. Drug Resistance, Neoplasm. Female. Humans. Mice. Mice, Nude. Neoplasm Transplantation. P-Glycoprotein / biosynthesis. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10671667.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] GREECE
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / P-Glycoprotein; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


20. Suzuki-Uematsu S, Shiraishi K, Ito T, Adachi N, Inage Y, Taeda Y, Ueki H, Ohtani H: Malignant phyllodes tumor composed almost exclusively of a fibrosarcomatous component: a case report and review of malignant phyllodes tumors with metastases. Breast Cancer; 2010 Jul;17(3):218-24
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant phyllodes tumor composed almost exclusively of a fibrosarcomatous component: a case report and review of malignant phyllodes tumors with metastases.
  • Here we present a case of malignant phyllodes tumor which was composed almost exclusively of a fibrosarcomatous component.
  • A 52-year-old Japanese female noted a rapid increase of her right breast tumor.
  • The tumor, 10 x 10 cm in the largest dimension, had somewhat of a pushing margin, and showed a flesh-like appearance with marked necrosis.
  • Microscopically, the tumor showed proliferation of atypical ovoid- or spindle-shaped cells in a myxoid matrix.
  • Multiple sectioning revealed that the tumor had only focal occurrence of elongated tubular structures, and the occurrence of a small component of benign phyllodes tumor, leading to the aforementioned final diagnosis.
  • Although the patient received adjuvant chemotherapy, no responsiveness was obtained.
  • We reviewed 15 malignant phyllodes tumors with metastases reported in Japan.
  • The estimated 2.2-year survival rate following detection of metastasis was 11%, thus confirming the aggressiveness of the disease.
  • [MeSH-major] Breast Neoplasms / pathology. Fibrosarcoma / pathology. Lung Neoplasms / secondary. Phyllodes Tumor / secondary
  • [MeSH-minor] Female. Humans. Mastectomy, Simple. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19350353.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  •  go-up   go-down


21. Tan EY, Tan PH, Yong WS, Wong HB, Ho GH, Yeo AW, Wong CY: Recurrent phyllodes tumours of the breast: pathological features and clinical implications. ANZ J Surg; 2006 Jun;76(6):476-80
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent phyllodes tumours of the breast: pathological features and clinical implications.
  • BACKGROUND: Phyllodes tumours (PT) of the breast are fibro-epithelial neoplasms that are known to recur locally in up to 19% of patients.
  • It is still debatable as to whether it is necessary to subject the patient to repeat surgery to obtain pathologically negative margins after a diagnosis of a benign or borderline PT is made.
  • Although the majority of recurrences are histologically similar to the initial tumour, a malignant recurrence is possible.
  • Malignant tumours can metastasize through the haematogenous route and metastases are associated with a poor prognosis as they are poorly responsive to conventional chemotherapy.
  • Data, including age at the time of diagnosis, clinical presentation, histological features, type of surgery carried out, clinical progression and characteristics of locally recurrent disease, were analysed.
  • Comparisons were made between those with benign, borderline and malignant tumours, as well as between those who developed a malignant recurrence and those who did not.
  • RESULTS: The mean age at the time of diagnosis was 39.6 +/- 7.4 years and the mean tumour size was 6.0 +/- 5.1 cm.
  • A total of 22 patients were classified as having benign tumour, 9 as having borderline tumour and 6 as having malignant tumour.
  • Tumour grade did not influence the tumour size, the adequacy of surgical margins or the time interval to local recurrence or the number of recurrences.
  • Although malignant tumours tended to recur earlier, this was not found to be statistically significant.
  • The majority of recurrent tumours were histologically similar to the initial tumour; however, seven patients (19%) developed a malignant recurrence from an initially benign or borderline tumour.
  • Distant metastasis developed only in patients with malignant tumours and accounted for all three mortalities in the study.
  • However, surgery for locally recurrent tumours, as well as malignant tumours, should aim to achieve adequate surgical margins to reduce the risk of local recurrence, particularly that of a malignant recurrence.
  • [MeSH-major] Breast Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Phyllodes Tumor / pathology
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Mastectomy. Middle Aged. Reoperation. Retrospective Studies. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] ANZ J Surg. 2006 Oct;76(10):956. Hoon, Tan Puay [corrected to Tan, Puay Hoon]; Hui, Ho G [corrected to Ho, Gay Hui]
  • (PMID = 16768772.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


22. Kok KY, Telesinghe PU, Yapp SK: Treatment and outcome of cystosarcoma phyllodes in Brunei: a 13-year experience. J R Coll Surg Edinb; 2001 Aug;46(4):198-201
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and outcome of cystosarcoma phyllodes in Brunei: a 13-year experience.
  • Cystosarcoma phyllodes is a rare tumour of the breast whose clinical behaviour does not correlate well with histological findings.
  • The optimal treatment of this tumour remains controversial.
  • A retrospective study on the treatment and outcome of women diagnosed with cystosarcoma phyllodes between 1986 and 1998 in Brunei was undertaken.
  • The mean age at diagnosis was 35 years.
  • There were 19 (73%) histologically benign lesions, 3 (12%) borderline lesions and 4 (15%) malignant lesions.
  • Four patients (16%) had recurrences after surgery (1 benign, 1 borderline and 2 malignant lesions).
  • Mean time to recurrence was 9 months.
  • Breast-conserving surgery with adequate resection margin is advocated in benign and borderline lesions.
  • For malignant lesions, simple mastectomy without routine axillary dissection is recommended.
  • More research is required to determine the role of adjuvant chemotherapy and radiotherapy in the management of malignant cystosarcoma phyllodes [corrected].
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / therapy. Phyllodes Tumor / pathology. Phyllodes Tumor / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy, Needle. Brunei. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Developing Countries. Female. Follow-Up Studies. Humans. Mastectomy / methods. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Severity of Illness Index. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J R Coll Surg Edinb 2001 Dec;46(6):339
  • (PMID = 11523709.001).
  • [ISSN] 0035-8835
  • [Journal-full-title] Journal of the Royal College of Surgeons of Edinburgh
  • [ISO-abbreviation] J R Coll Surg Edinb
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


23. Chen WH, Cheng SP, Tzen CY, Yang TL, Jeng KS, Liu CL, Liu TP: Surgical treatment of phyllodes tumors of the breast: retrospective review of 172 cases. J Surg Oncol; 2005 Sep 1;91(3):185-94
MedlinePlus Health Information. consumer health - Mastectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of phyllodes tumors of the breast: retrospective review of 172 cases.
  • BACKGROUND AND OBJECTIVES: Phyllodes tumors (PTs) are uncommon biphasic breast tumors that usually occur in adult females.
  • No one morphologic finding is reliable in predicting the clinical behavior of the tumor.
  • Clinical data analyzed included age, presenting symptoms and signs, tumor size, location, type of surgery, time to recurrence, and metastasis.
  • The majority of tumors were found in the upper outer quadrant (46.0%), with an equal propensity to occur in either breast (48.8% vs. 50.0%).
  • The pathologic diagnoses included 131 benign, 12 borderline, and 29 malignant lesions.
  • The initial diagnosis of all 19 recurrent tumors were benign.
  • Stromal cellularity, stromal overgrowth, stromal atypia, mitotic activity, tumor margin, and heterologous stromal elements were significantly correlated with metastases (P = 0.032, 0.00008, 0.000002, 0.004, 0.005, and 0.046, respectively).
  • Mammography and breast echo were not reliable for differentiating PTs from fibroadenomas (6.9% vs. 37.9% and 3.3% vs. 45%, respectively).
  • The role of adjuvant radiotherapy and chemotherapy remains to be defined.
  • The reasons for these procedures included a diagnosis of malignancy on frozen section or because the tumors were so large, they were assumed to be carcinomas.
  • Fifteen patients in our series had tumors with infiltrating tumor margin, severe stromal overgrowth, atypia, and cellularity.
  • CONCLUSIONS: Wide excision with a clear margin may be the preferable initial therapy, even for malignant PTs.
  • Patients have tumors with infiltrating tumor margin, severe stromal overgrowth, atypia, and cellularity are at high risk for metastases.
  • [MeSH-major] Breast Neoplasms / surgery. Mastectomy / methods. Phyllodes Tumor / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Mastectomy, Segmental. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies. Taiwan / epidemiology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16118768.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Darvishian F, Ginsberg MS, Klimstra DS, Brogi E: Carcinoid tumorlets simulate pulmonary metastases in women with breast cancer. Hum Pathol; 2006 Jul;37(7):839-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoid tumorlets simulate pulmonary metastases in women with breast cancer.
  • Cases of multiple PCTs diagnosed between 1992 and 2003 in patients with history of breast cancer were identified through a search of the pathology files.
  • We identified 12 women with a history of breast cancer and biopsy-proven PCTs, who were treated at our institution in a period of 12 years.
  • The mean age at diagnosis of the breast cancer was 62.8 years.
  • The breast cancer was invasive carcinoma in 10 cases (9 ductal and 1 lobular) and ductal carcinoma in situ and malignant phyllodes tumor in 1 case each.
  • Six women received radiotherapy; 5, chemotherapy; and 4, hormonal treatment, alone or in combination.
  • Pulmonary carcinoid tumorlets were identified within 5 months from diagnosis of the breast malignancy in 7 patients and at follow-up (range, 57-162 months) in the remaining 5.
  • None of the patients had known metastatic disease at the time of diagnosis of PCTs.
  • Three patients subsequently developed recurrent disease, including 2 with extramammary spread.
  • Pulmonary carcinoid tumorlets are radiologic and histologic mimickers of pulmonary metastases in patients with a history of breast cancer.
  • Consideration should be given to the possibility of PCTs in patients with breast cancer with pulmonary nodules, even if multiple.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoid Tumor / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Middle Aged. Tomography, X-Ray Computed






Advertisement